# Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

> **NCT04898309** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **AO GENERIUM**

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** GNR-038, 50 МЕ/ kg
- **DRUG:** GNR-038, 100 МЕ/ kg
- **DRUG:** Berinert®, 20 МЕ/ kg
- **DRUG:** Placebo
- **DRUG:** GNR-038. The dose will be selected according to results of stage 1 clinical trial.
- **DRUG:** Berinert®, 20 МЕ/ kg

## Key facts

- **NCT ID:** NCT04898309
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company pipeline revision
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898309, "Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04898309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*